Accordingly, Walker et al. reported a meta-analysis evaluating the safety and efficacy of DPP-4 inhibitors in T2D patients with CKD (defined as an eGFR < 60 mL/min/1.73 m2) and dialysis [126]. This evidence concerns the gene DPP4 and chronic kidney disease.